FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605996393> ?p ?o ?g. }

• W2605996393 endingPage "1421" @default.
• W2605996393 startingPage "1412" @default.
• W2605996393 abstract "Essentials•Annexin A5 resistance is a mechanism for antiphospholipid (aPL) syndrome.•750 patients with history of thrombosis, pregnancy complications and controls were tested.•Reduced annexin A5 anticoagulant ratios (A5R) correlate with aPL antibody multipositivity.•Reduced A5R may identify patients with a propensity for thrombosis or pregnancy complications.Click to hear an ISTH Academy presentation on antiphospholipid antibody syndrome by Drs de Laat and BertolacciniSummary BackgroundTAnnexin A5 (A5) is a potent anticoagulant protein that shields anionic phospholipids from coagulation reactions. Previous studies showed that antibodies from patients with antiphospholipid (aPL) syndrome (APS) interfere with annexin A5 crystallization and anticoagulant activity.ObjectiveThe purpose of this study was to investigate whether reduced values in the annexin A5 anticoagulant ratio (A5R) assay (i.e. ‘annexin A5 resistance’) are associated with adverse clinical events in aPL antibody‐positive patients.Patients/MethodsIn an initial discovery phase, a group of 679 patient samples from a ‘real‐world’ tertiary care hospital population were tested for A5R. This was followed by a validation‐phase cohort of 71 asymptomatic patients with aPL antibodies and no prior history of an adverse clinical event whose baseline samples were tested for A5R then subsequently observed for up to 4 years.ResultsIn the discovery‐phase group, we found a reduction of A5R in aPL antibody‐positive patients with thrombosis and/or pregnancy complications compared with aPL antibody‐negative patients and controls. In addition, reduced A5R values in both the discovery‐phase group and validation‐phase cohort correlated with the extent of multi‐positivity for standard APS tests, which has also been shown to be associated with a risk of adverse clinical outcomes.ConclusionReduced A5R values were associated with a multi‐positivity profile in aPL antibody‐positive patients within both groups and with the development of adverse clinical events. Essentials•Annexin A5 resistance is a mechanism for antiphospholipid (aPL) syndrome.•750 patients with history of thrombosis, pregnancy complications and controls were tested.•Reduced annexin A5 anticoagulant ratios (A5R) correlate with aPL antibody multipositivity.•Reduced A5R may identify patients with a propensity for thrombosis or pregnancy complications. •Annexin A5 resistance is a mechanism for antiphospholipid (aPL) syndrome.•750 patients with history of thrombosis, pregnancy complications and controls were tested.•Reduced annexin A5 anticoagulant ratios (A5R) correlate with aPL antibody multipositivity.•Reduced A5R may identify patients with a propensity for thrombosis or pregnancy complications. Click to hear an ISTH Academy presentation on antiphospholipid antibody syndrome by Drs de Laat and Bertolaccini TAnnexin A5 (A5) is a potent anticoagulant protein that shields anionic phospholipids from coagulation reactions. Previous studies showed that antibodies from patients with antiphospholipid (aPL) syndrome (APS) interfere with annexin A5 crystallization and anticoagulant activity. The purpose of this study was to investigate whether reduced values in the annexin A5 anticoagulant ratio (A5R) assay (i.e. ‘annexin A5 resistance’) are associated with adverse clinical events in aPL antibody‐positive patients. In an initial discovery phase, a group of 679 patient samples from a ‘real‐world’ tertiary care hospital population were tested for A5R. This was followed by a validation‐phase cohort of 71 asymptomatic patients with aPL antibodies and no prior history of an adverse clinical event whose baseline samples were tested for A5R then subsequently observed for up to 4 years. In the discovery‐phase group, we found a reduction of A5R in aPL antibody‐positive patients with thrombosis and/or pregnancy complications compared with aPL antibody‐negative patients and controls. In addition, reduced A5R values in both the discovery‐phase group and validation‐phase cohort correlated with the extent of multi‐positivity for standard APS tests, which has also been shown to be associated with a risk of adverse clinical outcomes. Reduced A5R values were associated with a multi‐positivity profile in aPL antibody‐positive patients within both groups and with the development of adverse clinical events." @default.
• W2605996393 created "2017-04-28" @default.
• W2605996393 creator A5001956462 @default.
• W2605996393 creator A5011151808 @default.
• W2605996393 creator A5012795067 @default.
• W2605996393 creator A5014408977 @default.
• W2605996393 creator A5025163038 @default.
• W2605996393 creator A5081304304 @default.
• W2605996393 date "2017-07-01" @default.
• W2605996393 modified "2023-09-30" @default.
• W2605996393 title "Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody‐positive patients with adverse clinical outcomes" @default.
• W2605996393 cites W137273772 @default.
• W2605996393 cites W1485863323 @default.
• W2605996393 cites W1526150545 @default.
• W2605996393 cites W1630341904 @default.
• W2605996393 cites W1922557247 @default.
• W2605996393 cites W1963872077 @default.
• W2605996393 cites W1975074770 @default.
• W2605996393 cites W1994288594 @default.
• W2605996393 cites W2002394202 @default.
• W2605996393 cites W2002611018 @default.
• W2605996393 cites W2009199902 @default.
• W2605996393 cites W2026309183 @default.
• W2605996393 cites W2042177086 @default.
• W2605996393 cites W2045485984 @default.
• W2605996393 cites W2050019577 @default.
• W2605996393 cites W2051506906 @default.
• W2605996393 cites W2054330426 @default.
• W2605996393 cites W2060104467 @default.
• W2605996393 cites W2062703398 @default.
• W2605996393 cites W2068581036 @default.
• W2605996393 cites W2078224498 @default.
• W2605996393 cites W2083687192 @default.
• W2605996393 cites W2086380144 @default.
• W2605996393 cites W2104266044 @default.
• W2605996393 cites W2118904149 @default.
• W2605996393 cites W2119266650 @default.
• W2605996393 cites W2138869304 @default.
• W2605996393 cites W2140168373 @default.
• W2605996393 cites W2142233457 @default.
• W2605996393 cites W2164810820 @default.
• W2605996393 cites W2170686017 @default.
• W2605996393 doi "https://doi.org/10.1111/jth.13699" @default.
• W2605996393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28393472" @default.
• W2605996393 hasPublicationYear "2017" @default.
• W2605996393 type Work @default.
• W2605996393 sameAs 2605996393 @default.
• W2605996393 citedByCount "12" @default.
• W2605996393 countsByYear W26059963932017 @default.
• W2605996393 countsByYear W26059963932018 @default.
• W2605996393 countsByYear W26059963932019 @default.
• W2605996393 countsByYear W26059963932020 @default.
• W2605996393 countsByYear W26059963932022 @default.
• W2605996393 countsByYear W26059963932023 @default.
• W2605996393 crossrefType "journal-article" @default.
• W2605996393 hasAuthorship W2605996393A5001956462 @default.
• W2605996393 hasAuthorship W2605996393A5011151808 @default.
• W2605996393 hasAuthorship W2605996393A5012795067 @default.
• W2605996393 hasAuthorship W2605996393A5014408977 @default.
• W2605996393 hasAuthorship W2605996393A5025163038 @default.
• W2605996393 hasAuthorship W2605996393A5081304304 @default.
• W2605996393 hasBestOaLocation W26059963931 @default.
• W2605996393 hasConcept C126322002 @default.
• W2605996393 hasConcept C159654299 @default.
• W2605996393 hasConcept C197934379 @default.
• W2605996393 hasConcept C203014093 @default.
• W2605996393 hasConcept C2776874634 @default.
• W2605996393 hasConcept C2777910003 @default.
• W2605996393 hasConcept C2778205648 @default.
• W2605996393 hasConcept C2779234561 @default.
• W2605996393 hasConcept C2780670749 @default.
• W2605996393 hasConcept C2780868729 @default.
• W2605996393 hasConcept C2908647359 @default.
• W2605996393 hasConcept C54355233 @default.
• W2605996393 hasConcept C553184892 @default.
• W2605996393 hasConcept C71924100 @default.
• W2605996393 hasConcept C72563966 @default.
• W2605996393 hasConcept C86803240 @default.
• W2605996393 hasConcept C88634738 @default.
• W2605996393 hasConcept C90924648 @default.
• W2605996393 hasConcept C99454951 @default.
• W2605996393 hasConceptScore W2605996393C126322002 @default.
• W2605996393 hasConceptScore W2605996393C159654299 @default.
• W2605996393 hasConceptScore W2605996393C197934379 @default.
• W2605996393 hasConceptScore W2605996393C203014093 @default.
• W2605996393 hasConceptScore W2605996393C2776874634 @default.
• W2605996393 hasConceptScore W2605996393C2777910003 @default.
• W2605996393 hasConceptScore W2605996393C2778205648 @default.
• W2605996393 hasConceptScore W2605996393C2779234561 @default.
• W2605996393 hasConceptScore W2605996393C2780670749 @default.
• W2605996393 hasConceptScore W2605996393C2780868729 @default.
• W2605996393 hasConceptScore W2605996393C2908647359 @default.
• W2605996393 hasConceptScore W2605996393C54355233 @default.
• W2605996393 hasConceptScore W2605996393C553184892 @default.
• W2605996393 hasConceptScore W2605996393C71924100 @default.
• W2605996393 hasConceptScore W2605996393C72563966 @default.
• W2605996393 hasConceptScore W2605996393C86803240 @default.
• W2605996393 hasConceptScore W2605996393C88634738 @default.

• next